Next 10 |
Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused...
2024-03-07 21:58:08 ET DBV Technologies S.A. (DBVT) Q4 2023 Earnings Conference Call March 07, 2024 05:00 PM ET Company Participants Katie Matthews - Investor Relations Daniel Tassé - Chief Executive Officer Pharis Mohideen - Chief Medical Officer Virgin...
2024-03-07 17:18:53 ET More on DBV Technologies Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies Read the full article on Seeking Alpha For further details...
Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) Strengthened exec...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...
Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on trea...
Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced...
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
2023-11-10 06:44:30 ET Summary DBV Technologies reports positive results for peanut allergy therapy in toddlers. Meta Platforms signs a deal with Tencent to sell a lower-priced version of its VR headset in China. BlackRock plans to create an Ethereum ETF, according to a filing...
2023-11-09 18:06:47 ET More on DBV Technologies DBV Technologies S.A. (DBVT) Q3 2023 Earnings Call Transcript Equitable Holdings Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies ...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Tec...
Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused...
Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut cl...